Shares of Bio-Techne Corp. TECH shed 2.04% to $58.73 Friday, on what proved to be an all-around poor trading session for the ...

Let’s dig into the relative performance of Bio-Techne (NASDAQ:TECH) and its peers as we unravel the now-completed Q4 research ...

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are covering the firm, Marketbeat.com reports. Four ...

Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region ...

Corporation announced further advancements in its ongoing strategy to bring translational discoveries to patient care by ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Argus analyst David Toung lowered the firm’s price target on Bio-Techne (TECH) to $90 from $95 and keeps a Buy rating on the shares after its ...

Dr. Gregory Bean, Associate Professor of Pathology at Stanford University, will describe the direct detection of mRNA from CRTC1/3::MAML2 translocations, as alternatives to MAML2 FISH, in the ...

Equities research analysts at Evercore ISI assumed coverage on shares of Bio-Techne (NASDAQ:TECH – Get Free Report) in a ...

In the preceding three months, 6 analysts have released ratings for Bio-Techne (NASDAQ:TECH), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates ...

This was the stock's second consecutive day of losses.